UMIN ID: UMIN000000705
Registered date:14/05/2007
Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer.
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | in patients with completely resected stage IB-IIIA non-small-cell |
| Date of first enrollment | 2007/01/01 |
| Target sample size | 20 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | treatment compliance rate is 70% or more. |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 80years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | Patients with incomplete resection, wedge resection, clinically significant cardiac dysfunction, active infection, Varicella, or critical complications, neurologic or psychiatric disorders, and patients who had had other cancers treated within the previous five years were ineligible. Pregnant woman were also ineligible. Patients decided to be unsuitable by the doctor was ineligible. |
Related Information
| Primary Sponsor | First Department of Surgery Hamamatsu University School of Medicine |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Nothing |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kazuhito Funai |
| Address | Japan |
| Telephone | |
| kfunai@hmedc.or.jp | |
| Affiliation | Hamamatsu University School of Medicine First Department of Surgery |
| scientific contact | |
| Name | Kazuya Suzuki |
| Address | 1-20-1 Handayama, Higashi, Hamamatsu, 431-3192,Japan Japan |
| Telephone | |
| Affiliation | Hamamatsu University School of Medicine First Department of Surgery |